Bristol Myers Squibb Highlights Oncology Innovation at Recent Convention
Cancer treatment is entering a new era, as advances in immunotherapy, cellular therapies and precision medicine reshape how physicians approach the disease
Increasingly personalized treatment options and new possibilities for managing certain cancers were the stars at the 2026 Annual Convention of the Puerto Rico Association of Hematologists and Medical Oncologists (AHOMPR), which brought together specialists from Puerto Rico, the United States and Europe to discuss the latest developments in cancer care.
“We are living through a very exciting time in medicine. We have many advancements, specifically in hematologic malignancies like leukemias, there are amazing therapies now that diminish all of the side effects that came with regular chemotherapies. Immunotherapy, for example, is leading treatment for patients with solid tumors,” said Dr. Dominic Sánchez Paredes, a hematologic oncologist who spoke with Caribbean Business in an exclusive interview.
Immunotherapy is a type of cancer treatment that uses the body’s own immune system to recognize, attack, and destroy cancer cells. Unlike chemotherapy, which directly targets rapidly dividing cells, immunotherapy helps the immune system fight cancer more effectively. Among the innovations being introduced is subcutaneous, meaning beneath the skin, administration for certain immunotherapies, offering an alternative to intravenous infusion in eligible settings.
Other forms of immunotherapy include CAR-T cell therapy, a form of cellular immunotherapy in which a patient’s immune cells are modified to target certain cancers, and precision medicine, which uses characteristics of a patient’s cancer, including tumor genetics, to help determine the most appropriate treatment.
BMS: Leaders in Oncology Innovation
These newer therapies may offer benefits such as longer survival, better disease management, additional treatment options and improvements in quality of life, depending on the cancer and treatment. Since 1967, Bristol Myers Squibb has been contributing to the research and development of more than 32 oncology products, transitioning from treating patients with similar diagnoses using similar approaches to tailoring treatments according to the biological characteristics of their disease.
“The field of medical oncology is one of the fields of medicine that has most changed in the last few years and that most changes day to day.”
Dr. Joel López Figueroa, President of AHOMPR
“We have been in operation in Puerto Rico for more than 50 years, and for us it is a privilege to be in a field that evolves so quickly. We were the first to bring immuno-oncology to the island, which is an extremely important advancement. We also established the necessary infrastructure to be able to offer cellular therapy in Puerto Rico and just two months ago, we were pioneers in a new class of treatments for multiple myeloma, a type of blood cancer that affects plasma cells,” said Dr. Maribelis Ruiz, Director of the Hematology, Oncology and Cell Therapy Business Unit at BMS Puerto Rico.
Puerto Rico currently has two authorized CAR-T treatment centers, one of them being at Hospital Auxilio Mutuo, in a special collaboration with BMS, allowing eligible patients to receive these treatments locally rather than traveling outside the island.
Dra. Maribelis Ruiz
BMS currently has 48 active development programs, 33 active research centers, and seven therapeutic areas in clinical studies. The company also has more than 20 strategic partnerships and collaborations in Puerto Rico, including partnerships between pharmaceutical companies and healthcare providers.
The Convention
The scientific program at the 2026 AHOMPR Annual Convention was based on a “Multidisciplinary Approach to Cancer Patient Care and Updates in Hematologic Malignancies”.
Physicians know that oncology is advancing rapidly, which is why it is important to remain informed about new research, treatment options and clinical practices. BMS participated as a premier sponsor of the event, because for the company, supporting the convention means supporting medical education and scientific exchange.
Dra. Dominic Sánchez Paredes
“The field of medical oncology is one of the fields of medicine that has most changed in the last few years and that most changes day to day. So, keeping up to date with all of the challenges, new therapies, and where those new treatments are headed, and the new strategies that are being introduced, not only in Puerto Rico but also on a global level, is extremely important,” said Dr. Joel López Figueroa, president of AHOMPR.
Some of the challenges the industry is currently facing are physician retention, access to specialized treatment, medical infrastructure and continued professional education; all themes the convention was developed to address. For Dr. López Figueroa, innovation alone cannot transform cancer care without the medical workforce and infrastructure needed to deliver it. That’s why retaining hematologists and oncologists in Puerto Rico is imperative, he stressed.
Looking ahead, BMS states that it projects more than 10 new medicines and over 30 potential launch opportunities globally by 2030. As scientific innovation continues to push the threshold of cancer treatment, experts suggest that progress means more than just the development of new therapies.
Ensuring that patients benefit from these advancements will require continued investment in medical education, research, infrastructure and collaboration among Puerto Rico’s healthcare professionals.
After volunteering at the Carolina food bank days after the midterms, about 60 officials heard the case for replacing the capped $2.98 billion NAP grant with SNAP in 2027, capitalizing on the Democratic wave